Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
Opus Genetics to Participate in February 2026 Medical and Industry Conferences
Opus Genetics, Inc. (Nasdaq: IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.
Collaborative Community on Ophthalmic Innovation (CCOI)
Topic: Opus Genetics leadership will participate in discussions focused on emerging treatment approaches and clinical insights in retinal disease.
Date: February 3-4, 2026
Location: Hong Kong
Asia-Pacific Academy of Ophthalmology Congress (APAO)
Topic: The Company will engage with the global ophthalmology community to discuss advances in gene therapy and evolving strategies for treating inherited retinal disorders.
Date: February 5-8, 2026
Location: Hong Kong
Advanced Therapies Week Conference
Title: Building scalable viral vector manufacturing models
Speaker: Chris Ernst, Chief Technology Officer, Opus Genetics
Date/Time: February 11, 2026, 10:30 – 11:00 AM PT
Location: San Diego, CA
The Macula Society Annual Meeting
Title: Preliminary Results from Sentinel Patient in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations
Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute
Date/Time: February 27, 2026, 7:15 – 7:20 AM PT
Location: San Diego, CA
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
COMTEX_473224577/2227/2026-02-09T18:57:46